<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11139310</article-id><article-id pub-id-type="pmc">2363602</article-id><article-id pub-id-type="pii">6691541</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1541</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gridelli</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Manzione</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Perrone</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Veltri</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cioffi</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Caprio</surname><given-names>M Grazia</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Frontini</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Rossi</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Barletta</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barzelloni</surname><given-names>M L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bilancia</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gallo</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Oncologia Medica B, Istituto Nazionale Tumori, Naples</aff><aff id="aff2"><label>2</label>Oncologia Medica, Ospedale S. Carlo, Potenza</aff><aff id="aff3"><label>3</label>Ufficio Sperimentazioni Cliniche Controllate, Istituto Nazionale Tumori, Naples</aff><aff id="aff4"><label>4</label>Oncologia Medica, Ospedale S. Maria Goretti, Latina</aff><aff id="aff5"><label>5</label>Pneumologia Oncologica, Ospedale Civile, Caserta</aff><aff id="aff6"><label>6</label>Oncologia Medica, Az. Ospedaliera Rummo, Benevento</aff><aff id="aff7"><label>7</label>Oncologia Medica, Ospedale S. Paolo, Milan</aff><aff id="aff8"><label>8</label>Statistica Medica, Seconda Universit&#x000e0;, Naples</aff><pub-date pub-type="epub"><day>01</day><month>01</month><year>2001</year></pub-date><pub-date pub-type="ppub"><month>01</month><year>2001</year></pub-date><volume>84</volume><issue>1</issue><fpage>38</fpage><lpage>41</lpage><history><date date-type="received"><day>17</day><month>05</month><year>2000</year></date><date date-type="rev-recd"><day>15</day><month>08</month><year>2000</year></date><date date-type="accepted"><day>13</day><month>09</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A multicentre phase 2 trial (single-stage design) was undertaken to test the efficacy and toxicity of carboplatin (AUC 6 according to Calvert) plus paclitaxel (175 mg/m<sup>2</sup>3-h infusion) every 4 weeks in the first line treatment of patients affected by extensive small cell lung cancer. The primary end-point of the trial was the objective response rate. 31 objective responses among 50 patients were considered necessary to proceed to a phase 3 trial. 48 patients were enrolled (median age 59 years). Treatment was very well tolerated. 3 patients (6.2&#x00025;) had a complete response and 23 (47.9&#x00025;) a partial response, for an overall response rate of 54.2&#x00025; (95&#x00025; CI: 39.2&#x02013;68.6) Median time to progression was 5.7 months (95&#x00025; CI: 5.2&#x02013;6.2). Median survival was 9.6 months (95&#x00025; CI: 7.2&#x02013;14.6), with a median follow-up time of alive patients of 12 months. At 1 year, the probability of being progression-free or alive was 0.16 and 0.43, respectively. In conclusion, carboplatin plus paclitaxel as given in the present study is very well tolerated but not sufficiently active to warrant phase 3 comparison with standard chemotherapy regimens. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>paclitaxel</kwd><kwd>carboplatin</kwd><kwd>small cell lung cancer</kwd></kwd-group></article-meta></front></article>


